Kye Pharmaceuticals, Inc. ("Kye") announced today that ACCRUFeR® (ferric maltol) is now available across Canada. ACCRUFeR® is ...

The London-based company said the FDA had approved its lead product Ferracru/Accrufer (ferric maltol) in a market that could be worth $1 billion annually. The FDA approved the product for ...

Commercial stage pharmaceutical company Shield Therapeutics, which has operations in Gateshead, has officially launched in Canada.

The firm’s lead drug is sold as Accrufer in the US, and Ferracru in the UK and Europe. READ MORE: Carmarthenshire ...

The company expects to report total revenues of $32.2m for FY24, up from $17.5m in the prior year. Total ACCRUFeR prescriptions grew by 95 per cent to about 150,000, generating $29.3m - an increase of ...

From the Shield side, as of 1 April 2023, Shield now has 33 dedicated sales representatives and 5 Regional Sales Managers (RSM) currently promoting Accrufer® to Women's Health and General ...